MediPoint: In-Vitro Colorectal Cancer Screening Tests - Global Analysis and Market Forecasts


#172818

383pages

GlobalData

$ 6495

In Stock

Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

Questions Answered in this Report
  • Colorectal cancer can be caused by somatic mutations as well as inherited mutations. These mutations lead to changes in the colon, that can be detected by detection of bleeding. But many of these mutations can be also be detected by genetic and other tests. How quickly will new gene tests be adopted by the CRC screening market??
  • What are the key differences in CRC screening carried out in different countries, and how will these differences affect adoption of new screening tests?
  • Existing CRC screening is based on inexpensive, but inaccurate stool analysis tests, or expensive but accurate endoscopies. The first DNA screening tests are expected to come to market in 2014, from Exact Sciences and EpiGenomics. Which new DNA-based screening test will win out ?
  • In-vitro CRC screening is a fast evolving technological area. How will change in technology affect sales of existing CRC screening tests? Who are the new players in CRC screening? How will patient attitudes affect the In-vitro CRC screening test market?